Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYO9A antisense RNA 1 (MYO9A-AS1) is a predicted long non-coding RNA transcript located antisense to the MYO9A gene. Its specific sequence, biological function, and relevance as a therapeutic target are uncharacterized. In general, antisense RNAs may regulate their sense gene partners at the transcriptional or post-transcriptional level, but no direct data exists for MYO9A-AS1. There is no evidence of disease association, drug targeting, or biomarker relevance for MYO9A-AS1, and it should not be considered a validated drug target. This entry is likely to be a gene prediction or annotation artifact, rather than a functionally established molecular entity. Caution should be exercised when considering MYO9A-AS1 as a drug target, biomarker, or having any clinical significance.
No specific mechanisms available for MYO9A-AS1; for antisense RNAs in general: Can modulate mRNA stability, translation, or epigenetic marks. Antisense oligonucleotides can induce RNase H-mediated RNA degradation (general for antisense therapy, not for MYO9A-AS1 specifically).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYO9A antisense RNA 1 (MYO9A-AS1).